SVF Pauling (Cayman) Ltd 4
4 · Relay Therapeutics, Inc. · Filed Jul 21, 2020
Insider Transaction Report
Form 4
SVF Pauling (Cayman) Ltd
10% Owner
Transactions
- Conversion
Series C Convertible Preferred Stock
2020-07-20−99,088,292→ 0 total(indirect: See Footnote)→ Common Stock (27,904,963 underlying) - Conversion
Common Stock
2020-07-20+27,904,963→ 27,904,963 total(indirect: See Footnote)
Footnotes (2)
- [F1]Represents securities held directly by SVF Pauling (Cayman) Limited, a wholly owned subsidiary of SoftBank Vision Fund (AIV M2) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions relating to the acquisition, structuring, financing and disposal of SVF's investments. SBIA UK disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission that any reporting person is the beneficial owner of such shares for purposes of the Securities Exchange Act of 1934 or for any other purpose.
- [F2]Each share of Series C Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date.